2D-BioPAD and MUNASET Join Forces at Graphene Week 2026
For the third consecutive year, 2D-BioPAD and MUNASET joined forces during Graphene Week 2026 to organise their joint...
Read more
Supple Graphene Bio-Platform for point-of-care early detection and monitoring of Alzheimer’s Disease.
Learn moreIn a Nutshell
2D-BioPAD is pioneering a graphene-based Point-of-Care (PoC) In-Vitro Diagnostics (IVD) system for early Alzheimer’s Disease (AD) detection. This non-invasive solution, using 2D materials, can identify and quantify up to 5 AD biomarkers in real-time. Clinical pilot studies in Finland, Greece, and Germany aim to demonstrate its impact, with a focus on safety, ethics, and seamless integration into primary healthcare settings.
Latest News
2D-BioPAD & MUNASET team up again at Graphene Week 2026
For the third consecutive year, the 2D-BioPAD and MUNASET projects are joining forces at Graphene Week 2026 to...
Read more
2D-BioPAD at Health Insight 2026
The 2D-BioPAD project was represented at Health Insight 2026, held in Kuopio, Finland, on August 19-20, 2026, by...
Read more
2D-BioPAD at Graphene 2026 in Barcelona
From 30 June to 3 July 2026, the 2D-BioPAD project participated in Graphene 2026, held in Barcelona, Spain....
Read more
Consortium Partners
